Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: An observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial

BMJ Open

Volumn 2, Issue 6, 2012, Pages

  Preiss, David ^a   Thomas, Laine E ^b   Sun, Jie Lena ^b   Haffner, Steven M ^c   Holman, Rury R ^d   Standl, Eberhard ^e   Leiter, Lawrence A ^f   Mazzone, Theodore ^g   Rutten, Guy E ^h   Tognoni, Gianni ⁱ   Martinez, Felipe A ^j   Chiang, Fu Tien ^k   Califf, Robert M ^l   McMurray, John J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e Helmholtz Centre   (Germany)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g UNIVERSITY OF ILLINOIS   (United States)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ Consorzio Mario Negri Sud ^*  (Italy)

^j UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^k NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^l DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NATEGLINIDE; PLACEBO; VALSARTAN;

ADULT; AGING; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAM; FEMALE; FRAMINGHAM RISK SCORE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; ORAL GLUCOSE TOLERANCE TEST; OUTCOMES RESEARCH; PREDICTION; PRIMARY PREVENTION; PROPORTIONAL HAZARDS MODEL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SEX DIFFERENCE; SMOKING; SYSTOLIC BLOOD PRESSURE; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 84871004262     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-001925     Document Type: Article

References (21)

1. DECODE Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397-405.
2. Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol 2010;55:1310-17.
3. Karve A, Hayward RA. Prevalence, diagnosis, and treatment of impaired fasting glucose and impaired glucose tolerance in nondiabetic U.S. adults. Diabetes Care 2010;33:2355-9.
4. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47. (Pubitemid 28213628)
5. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008;336:1475-82. (Pubitemid 351977019)
6. Elley CR, Robinson E, Kenealy T, et al. Derivation and validation of a new cardiovascular risk score for people with type 2 diabetes: the New Zealand diabetes cohort study. Diabetes Care 2010;33:1347-52.
7. Zethelius B, Eliasson B, Eeg-Olofsson K, et al. A new model for 5-year risk of cardiovascular disease in type 2 diabetes, from the Swedish National Diabetes Register (NDR). Diabetes Res Clin Pract 2011;93:276-84.
8. Kengne AP, Patel A, Marre M, et al. Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. Eur J Cardiovasc Prev Rehabil 2011;18:393-8.
9. van Dieren S, Beulens JW, Kengne AP, et al. Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review. Heart 2012;98:360-9.
10. Krum H, McMurray JJ, Horton E, et al. Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials. Cardiovasc Ther 2010;28:124-32.
11. Holman RR, Haffner SM, McMurray JJ, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1463-76.
12. McMurray JJ, Holman RR, Haffner SM, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1477-90.
13. Sidney S, Sorel M, Quesenberry CP Jr, et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005;128:2068-75.
14. Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006;16:63-70. (Pubitemid 41783891)
15. Sarnak MJ, Tighiouart H, Manjunath G, et al. Anemia as a risk factor for cardiovascular disease in the Atherosclerosis Risk in Communities (ARIC) study. J Am Coll Cardiol 2002;40:27-33. (Pubitemid 34701373)
16. Abramson JL, Jurkovitz CT, Vaccarino V, et al. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC study. Kidney Int 2003;64:610-15. (Pubitemid 36871933)
17. Brown DW, Giles WH, Croft JB. Hematocrit and the risk of coronary heart disease mortality. Am Heart J 2001;142:657-63. (Pubitemid 32900492)
18. Vlagopoulos PT, Tighiouart H, Weiner DE, et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol 2005;16:3403-10. (Pubitemid 46179344)
19. Ng AC, Chung T, Yong AS, et al. Long-term cardiovascular and noncardiovascular mortality of 1023 patients with confirmed acute pulmonary embolism. Circ Cardiovasc Qual Outcomes 2011;4:122-8.
20. Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010;362:800-11.
21. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-60.